Bergen, Norway, 11 June 2021

The Board of Directors in BerGenBio ASA (the "Company") (OSE: BGBIO) have, to
fulfil the Company's obligations under the share option agreements and in
accordance with the authorization granted by the general meeting on 19 March
2021, today resolved to increase the Company's share capital by NOK 7,500 by
issuance of 75,000 new shares. The new shares are subscribed for by option owner
who wishes and are entitled to exercise options in accordance with the Company's
option scheme. Each option gives a right to receive one share in the Company.
The subscription price is in accordance with the prevailing options price
pursuant to the Company´s option scheme NOK 10.62 per share.

The 75,000 options are exercised by primary insider Richard Godfrey (CEO) and
the options are granted 13 June 2013 and expiry on 13 June 2021. Primary insider
notification pursuant to the market abuse regulation article 19 is attached.

The primary insider has transferred his rights to receive shares resulting from
the exercise of options to a third party. The third party has sold the shares at
a price of NOK 25.67 per share.

Following the exercise, primary insider Richard Godfrey are holding 1,684,978
options in the Company of which 1,096,462 is vested, in addition to 21,005
shares in the Company through Gnist Holding AS.

The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 8,796,275.50 consisting of 87,962,755 shares, each with a par value of
NOK 0.10.

-End-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and section 5-12 of the Norwegian Securities
Trading Act.